interstitial lung disease | Search results

Showing 31 to 32 of 32 results for interstitial lung disease

Sort by

Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]
Discontinued Reference number: GID-TA10566
Result type
Technology appraisal guidance
Status
Discontinued
NICE real-world evidence framework (ECD9)
This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence